Gyermekkori daganatok: vizsgálatok itt: Dél-Korea
49 of 64 trials · From ClinicalTrials.gov, checked 2026. november 19.. Ask the study team whether a trial fits you.
- 1/2. fázisFut, nem toborozTrial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Where
- Seoul
- People
- 64 worldwide
- Run by
- RayzeBio, Inc.
See details and how to joinNCT06590857 - 1/2. fázisTaking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Seoul
- Életkor
- 6 hónap to 17 év
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - 2. fázisBefejeződöttBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Jongno-gu, Songpa-gu
- Életkor
- 12 év and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - 1/2. fázisTaking peopleStudy of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 83 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00 - 1/2. fázisTaking peopleSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
- Where
- Seoul
- Életkor
- 1 év to 30 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07387926 - 3. fázisTaking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Daegu, Goyang-si, Gyeonggi-do, Seoul
- Életkor
- 15 év and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - 2. fázisTaking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Seoul
- Életkor
- 1 év to 18 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - 2. fázisTaking peopleA Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
- Where
- Seoul
- Életkor
- 12 év to 17 év
- People
- 15 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07700758 · EU 2025-524515-37-00 - 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Busan, Jeollanam, Seoul, Uijeongbu-si
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - 1/2. fázisTaking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Goyang-si, Seoul
- Életkor
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - 3. fázisTaking peopleA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- Where
- Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00 - 1/2. fázisTaking peopleA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Seoul
- Életkor
- 6 hónap to 30 év
- People
- 65 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05533775 - 1/2. fázisTaking peopleA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Where
- Seoul
- Életkor
- 2 év and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00 - 2/3. fázisTaking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Seoul
- People
- 1541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Seoul
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 1/2. fázisTaking peopleA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Seoul
- Életkor
- 1 hónap to 17 év
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - 1/2. fázisTaking peopleStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Seoul
- Életkor
- 16 év and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00 - 3. fázisTaking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Busan, Daegu, Goyang-si, Seoul
- Életkor
- 12 év and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - 2. fázisTaking peopleONO-4538 Phase II Rollover Study (ONO-4538-98)
- Where
- Daegu, Gyeonggi-do, Hwasun, Incheon, Seoul, Suwon
- Életkor
- 16 év and over
- People
- 70 worldwide
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT04566380 - 1/2. fázisTaking peopleAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 255 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00 - 1/2. fázisTaking peopleAZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 161 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00 - 1/2. fázisTaking peopleStudy to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
- Where
- Gyeonggi-do, Seoul
- Életkor
- 12 év and over
- People
- 78 worldwide
- Run by
- MedPacto, Inc.
See details and how to joinNCT05588648 - 2/3. fázisTaking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Daegu, Seoul
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - 1/2. fázisTaking peopleA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Seoul
- Életkor
- 1 hónap to 17 év
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - 1. fázisTaking peopleA Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Seoul
- Életkor
- 6 hónap to 17 év
- People
- 18 worldwide
- Run by
- AbbVie
See details and how to joinNCT07306832